Dexcom is suddenly the San Diego company everyone from Wall Street to City Hall is watching. At its latest investor day, the glucose-monitoring giant laid out a packed to-do list of new products and insurance wins that, if it all actually happens, could send a serious wave of jobs, contracts and local spending across the region over the rest of the decade.
Local officials and analysts say this is not pocket change. Dexcom has already poured major dollars into its San Diego base, and if the company comes close to hitting its own targets, the plan could steer more than $800 million into the region through 2030, with recent investments alone topping half a billion dollars. As reported by the San Diego Union-Tribune, that math is a big part of the argument for keeping product engineering and manufacturing anchored here instead of somewhere cheaper.
Investor day and governance moves
At its May investor day, Dexcom rolled out a long-range roadmap and paired it with a governance makeover tied to its engagement with activist investor Elliott Management. In a press release via Business Wire, the company said it plans to add two independent directors and expand a key board committee’s responsibilities so it more directly oversees operations and quality.
The event also came with fresh financial targets and a clearer capital-allocation script that investors zeroed in on, including a new share-repurchase authorization and explicit commitments to keep funding R&D while pushing margins higher through the end of the decade.
Numbers: revenue, users and coverage
Dexcom wrapped 2025 with multi‑billion dollar sales and told investors it is aiming for more of the same double‑digit‑ish growth going forward. The company reported roughly $4.6 billion in revenue last year and guided to about $5.16–$5.25 billion for 2026, pointing to steady growth in users and broader commercial coverage that could open access to millions more people…